News Center
With the tenet of "Healthy China, Dedicated commitment", Linuo Pharmaceuticals increases cooperation and association with external scientific research institutes while innovating and developing independently.
16
2026
-
06
Linuo Pharmaceutical unveils its 2026 Starry Night Summit, with a glorious coronation that underscores its formidable strength!
Classification：
Corporate News
On the 16th, the Sixth China Pharmaceutical Distribution and Trade Conference and the World Pharmaceutical Retail Congress (2026 Starlight Summit) kicked off with great fanfare. As a highly influential industry event in the pharmaceutical retail sector, this year’s conference is themed “Smart Chains Without Borders, Starting from e,” bringing together leading professionals from across the nation’s pharmaceutical manufacturing, retail chains, and commercial distribution sectors to jointly explore new pathways for high-quality industry development.
Lino Pharmaceutical, a wholly owned subsidiary of Keyuan Pharmaceutical (301281.SZ), was invited to exhibit, making a high‑profile appearance with its comprehensive product portfolio. The company engaged in in-depth discussions with industry peers, won multiple prestigious industry awards, and demonstrated robust growth momentum through its strong technical capabilities, emerging as a standout enterprise at this year’s conference.
At the meeting, Chairman Li Hongfu delivered an in-depth keynote address, systematically outlining the company’s core strengths and its future product roadmap to the attendees.
With more than two decades of deep expertise in the pharmaceutical sector, Linuo Pharmaceutical leverages the core strengths of its parent company, Keyuan Pharmaceutical—integrated API–formulation and excipient–formulation capabilities—to build a comprehensive product pipeline spanning cardiovascular, antidiabetic, central nervous system, anti-inflammatory and antibacterial, and respiratory therapeutic areas. Several of its products have passed generic drug consistency evaluations and won bids in national centralized procurement, maintaining a leading position in market competitiveness.
In recent years, Linuo Pharmaceutical has accelerated its digital and intelligent transformation, building an AI‑powered, high‑performance smart factory that encompasses production lines for oral solid and liquid formulations as well as injectables, thereby boosting both production efficiency and product quality. At the same time, the company has advanced AI‑driven applications across all scenarios, empowering the entire value chain—from R&D and manufacturing to quality control and distribution—thus laying a solid foundation for high‑quality development.
Going forward, Linuo Pharmaceutical will continue to ramp up its product investments, focusing on market needs and pain points while proactively exploring and expanding into cutting-edge areas such as glucose‑lowering and weight‑management products, anti‑aging solutions, and brain‑machine interfaces. The company will refine its comprehensive, all‑scenario product portfolio, offering differentiated, highly competitive offerings to end‑users and helping partners broaden their market share. From product R&D to smart manufacturing, from channel empowerment to point‑of‑sale services, Linuo Pharmaceutical remains committed to leveraging its end-to-end strengths to inject new momentum into the pharmaceutical retail sector and deliver greater value to its partners.
At the exhibition booth, Linuo Pharmaceutical showcased its full range of product formulations and categories, unveiling flagship new products such as Diphenhydramine Hydrochloride Tablets, Oseltamivir Phosphate Granules, and Betahistine Hydrochloride Tablets. The company’s diversified product portfolio drew significant attention from industry peers and strategic partners.
The marketing team leverages high-quality products and efficient services to strengthen industry collaboration, engaging in numerous in-depth discussions with chain pharmacies and business partners. Together, they explore new avenues for cooperation and map out a fresh roadmap for development across key areas such as product empowerment, joint channel development, and market expansion.
In recognition of its outstanding contributions to the pharmaceutical retail sector, its sustained R&D innovation, and its reputation for high‑quality, reliable products, Linuo Pharmaceutical has been honored with several prestigious awards. Chairman Li Hongfu, with years of deep industry experience, has spearheaded the company’s leap‑forward growth through forward‑looking strategic planning and meticulous operational excellence, earning him the “Starry Elite” award and underscoring his leadership in the field. Its flagship product, Diphenhydramine Hydrochloride Tablets, was named a “Starry Quality Product,” becoming a benchmark item in retail channels. Furthermore, the company was bestowed the title of “Outstanding Supporting Enterprise” for its robust support of industry development and its collaborative contributions across the value chain. These three accolades collectively reflect the industry’s high regard for Linuo Pharmaceutical’s comprehensive strength.
The stellar performance of the 2026 Starlight Conference is a microcosm of Linuo Pharmaceutical’s achievements and, at the same time, an important starting point as it embarks on a new journey.
Looking ahead, Linuo Pharmaceutical will remain committed to its core values of “long-termism, product‑centricity, and altruism,” leveraging innovation as its primary engine. The company will continue to strengthen its integrated API–formulation capabilities, accelerate the development of new products and their market deployment, and deepen collaboration with industry peers and partners. By pooling resources and driving synergies, Linuo aims to propel the pharmaceutical sector toward high‑quality growth and write a new chapter of success in the wave of pharmaceutical advancement in the new era.
Related news
2026-05-18
On May 16–17, Wu Xiaobo, known as “China’s foremost financial writer” and a renowned entrepreneur, led a delegation to visit and inspect Keyuan Pharmaceutical (stock code: 301281.SZ). The group focused on the company’s achievements in integrating smart manufacturing with digital AI technologies in the pharmaceutical sector, engaged in in-depth discussions with its core management team, and expressed high praise for the company’s practical approach to driving industrial upgrading through digital and intelligent transformation. Gao Yuankun, Chairman and President of Linuo Group, along with Li Hongfu, Chairman of Keyuan Pharmaceutical, and Wei Zhiguo, President of the company, accompanied the delegation during the visit.
ADD：#30766 Jingshidong Road, Linuo High-tech Park, Jinan, Shandong Province, P. R. China